Skip to content

Comparison of two photo therapy methods in treating Vitiligo

Comparison of Psoralen–narrowband UVB and narrowband UVB in treating Vitiligo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017052816955N6
Enrollment
60
Registered
2017-06-08
Start date
2015-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized vitiligo. Vitiligo

Interventions

Intervention 1: Photo therapy using NB-UVB with initial dose of 0.25 J/cm2 three sessions in a week plus 8-Metoxi Pesoralen with dose of 0.6mg/kg two hours before photo therapy. Intervention 2: Photo
Treatment - Drugs
Photo therapy using NB-UVB with initial dose of 0.25 J/cm2 three sessions in a week plus 8-Metoxi Pesoralen with dose of 0.6mg/kg two hours before photo therapy.
Photo therapy using 0.6mg/kg with initial dose of 0.25 J/cm2 three sessions in a week

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with generalized Vitiligo who have 5 to 60 percent body involvement; filling out consent form by patient; age over 13 years old Exclusion criteria: patients who have been under phototherapy or photochemotherapy during 3 months before study starts; patients who have had over 100 phototherapy or photochemotherapy sessions before; pregnancy or breast feeding; heart, kidney and liver disease; children under 13 years old; history of photosensitivity or any dermatosis created by UV light like Lupus Erythematosus; history of previous skin malignancy; history of cataract

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Extent of lesion. Timepoint: Before starting treatment and after each 20 sessions. Method of measurement: Taking photos and measuring in hand unit and each hand unit is equal to 1 percent.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zahra Ashrafi

Mashhad University of Medical Sciences

src@mums.ac.ir+98 51 3801 2493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026